Sequentify

growth-positive

Sequentify has announced the appointment of Dr. Ravi Majeti as a Scientific Advisor. Dr. Majeti is a renowned expert in hematologic malignancies and holds a prestigious position at Stanford University. His expertise will aid Sequentify in expanding its portfolio of hematology-focused NGS panels and promoting the adoption of its genomic testing solutions in academic and clinical settings. Sequentify, a Weizmann Institute spinoff founded in 2021, focuses on decentralized genomic sequencing, offering solutions for oncology, screening, and infectious diseases. The company aims to address industry pain points with its sample-prep and software solutions, facilitating scalable genomic testing.

growth-positive

Sequentify and Bio Molecular Systems (BMS) have announced the release of the InfiniSeq Protocol for the Myra liquid handling system. This collaboration combines Sequentifys targeted sequencing chemistry with BMSs automation technology, enabling high-throughput library preparation. The InfiniSeq Protocol allows for the preparation of up to 96 indexed libraries in a single run, reducing hands-on time and errors. It is designed for clinical and research applications, including oncology panels. This partnership aims to decentralize genomic testing and make it more accessible. Sequentify, a Weizmann Institute spinoff, focuses on providing scalable genomic testing solutions, while BMS specializes in life sciences instrumentation.

growth-positive

Sequentify, a Weizmann Institute spinoff founded in 2021, is offering research grants to accelerate genomic studies using its scalable targeted library preparation technology. The company invites proposals from research groups conducting genomic DNA studies with human samples, focusing on areas like oncology, rare diseases, and infectious diseases. Selected applicants will receive reagents for up to 10,000 samples and access to Sequentifys analysis software. The application period is from April 5 to June 20, 2025. Sequentify aims to facilitate large-scale genomic testing by addressing industry pain points with its sample-prep and software solutions. The company is based in Rehovot, Israel, and focuses on the clinical market.

growth-positive

Sequentify has partnered with Sheba Medical Centers Hematology Laboratory and other leading clinicians to conduct a joint study using Sequentifys InfiniSeq™ Myeloid Malignancies Panel. The study aims to identify Clonal Hematopoiesis of Indeterminate Potential (CHIP) in patients previously diagnosed with solid tumors, potentially advancing personalized medicine in oncology. The InfiniSeq technology offers a streamlined and cost-effective sequencing process, enhancing lab capabilities. This collaboration underscores Sheba Medical Centers commitment to diagnostic innovation and improving patient outcomes.

growth-positive

Sequentify has partnered with Dexter, a Romanian distributor, to introduce its InfiniSeq™ library preparation solutions to Romania. This partnership aims to expand access to advanced genomic diagnostics in the region. The InfiniSeq protocol reduces sample preparation time significantly and is compatible with most sequencing machines, making it a practical choice for laboratories. Dexter plans to introduce additional Sequentify products, including tools for infectious disease diagnostics and oncology panels, enhancing the scope of genomic diagnostics in Romania. Sequentify is also working with other distributors across Europe to bring their products to global markets.